Talk to Immutep Limited directly.
Sign up to their Investor Hub for direct access to the Immutep Limited team, ask them questions, and see personal updates.
Immutep Limited are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S. They are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by their Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. Their objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. They have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Level 12/95 Pitt St, Sydney NSW 2000, Australia
Earnings per share
Dividend per share